ProPhase Labs, Inc. Current Liabilities
ProPhase Labs, Inc. (PRPH) had Current Liabilities of $58.09 million as of 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-19
- 2026-06-30: Liabilities, Current $58.09M.
- 2026-03-31: Liabilities, Current $55.67M; Liabilities, Current as first filed $56.11M.
- 2025-12-31: Liabilities, Current $53.08M.
- 2025-09-30: Liabilities, Current $55.29M.
| Period end | Liabilities, Current | Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $58.09M 10-Q · filed 2026-08-19 | |
| 2026-03-31 | $55.67M 10-Q/A · filed 2026-07-09 | $56.11M 10-Q · filed 2026-06-30 |
| 2025-12-31 | $53.08M 10-Q · filed 2026-08-19 | |
| 2025-09-30 | $55.29M 10-Q · filed 2025-11-19 | |
| 2025-06-30 | $25.63M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $24.05M 10-Q · filed 2025-05-20 | |
| 2024-12-31 | $32.13M 10-K · filed 2026-06-01 | |
| 2024-09-30 | $28.70M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $28.01M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $23.91M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $20.86M 10-K · filed 2025-04-01 | |
| 2023-09-30 | $16.41M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $13.68M 10-Q · filed 2023-08-11 | |
| 2023-03-31 | $18.47M 10-Q · filed 2023-05-12 | |
| 2022-12-31 | $16.07M 10-K · filed 2024-03-29 | |
| 2022-09-30 | $16.69M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $16.72M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $19.77M 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $15.52M 10-K · filed 2023-03-29 | |
| 2021-09-30 | $9.93M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $14.17M 10-Q · filed 2021-08-13 | |
| 2021-03-31 | $18.29M 10-Q · filed 2021-05-14 | |
| 2020-12-31 | $6.29M 10-K · filed 2022-03-31 | |
| 2020-09-30 | $2.15M 10-Q · filed 2020-11-19 | |
| 2020-06-30 | $1.40M 10-Q · filed 2020-08-11 | |
| 2020-03-31 | $1.13M 10-Q · filed 2020-05-12 | |
| 2019-12-31 | $933.00K 10-K · filed 2021-03-31 | |
| 2019-09-30 | $1.07M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $956.00K 10-Q · filed 2019-08-12 | |
| 2019-03-31 | $870.00K 10-Q · filed 2019-05-14 | |
| 2018-12-31 | $4.23M 10-K · filed 2020-03-26 | |
| 2018-09-30 | $876.00K 10-Q · filed 2018-11-14 | |
| 2018-06-30 | $1.59M 10-Q · filed 2018-08-20 | |
| 2018-03-31 | $1.84M 10-Q/A · filed 2018-08-20 | $1.10M 10-Q · filed 2018-05-15 |
| 2017-12-31 | $1.81M 10-K · filed 2019-03-26 | $1.07M 10-K · filed 2018-03-28 |
| 2017-09-30 | $3.18M 10-Q/A · filed 2018-08-20 | $2.43M 10-Q · filed 2017-11-13 |
| 2017-06-30 | $4.22M 10-Q/A · filed 2018-08-20 | $3.47M 10-Q · filed 2017-08-11 |
| 2017-03-31 | $7.62M 10-Q/A · filed 2018-08-20 | $6.87M 10-Q · filed 2017-05-15 |
| 2016-12-31 | $6.84M 10-Q/A · filed 2018-08-20 | |
| 2016-09-30 | $6.25M 10-Q · filed 2016-11-14 | |
| 2016-06-30 | $5.18M 10-Q · filed 2016-08-11 | |
| 2016-03-31 | $4.36M 10-Q · filed 2016-05-13 | |
| 2015-12-31 | $4.53M 10-K · filed 2017-02-24 | |
| 2015-09-30 | $3.71M 10-Q · filed 2015-11-13 | |
| 2015-06-30 | $3.58M 10-Q · filed 2015-08-12 | |
| 2015-03-31 | $5.52M 10-Q · filed 2015-05-13 | |
| 2014-12-31 | $5.24M 10-K · filed 2016-03-29 | |
| 2014-09-30 | $7.18M 10-Q · filed 2014-11-13 | |
| 2014-06-30 | $5.95M 10-Q · filed 2014-08-12 | |
| 2014-03-31 | $4.26M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $4.62M 10-K · filed 2015-03-27 | |
| 2013-09-30 | $4.74M 10-Q · filed 2013-11-13 | |
| 2013-06-30 | $4.47M 10-Q · filed 2013-08-13 | |
| 2013-03-31 | $3.86M 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $4.91M 10-K · filed 2014-03-27 | |
| 2012-09-30 | $6.64M 10-Q · filed 2012-11-14 | |
| 2012-06-30 | $6.40M 10-Q · filed 2012-08-13 | |
| 2012-03-31 | $7.30M 10-Q · filed 2012-05-11 | |
| 2011-12-31 | $7.85M 10-K · filed 2013-03-28 | |
| 2011-09-30 | $7.57M 10-Q · filed 2011-11-14 | |
| 2011-06-30 | $5.79M 10-Q · filed 2011-08-12 | |
| 2010-12-31 | $8.23M 10-K · filed 2012-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |